REVIEW ARTICLE

Enhancing Cardiovascular Health with the Implementation of Digitalis

Nisha D Barole[1*], Gaurav S Mude[1], Kuntal P Godde[1], Shreya V Tenpe[1]

[1]*School of Allied Health Sciences, DMIHER (DU), Sawangi (M), Wardha, Maharashtra, India-442001;*
[2]*Datta Meghe College of Pharmacy, DMIHER (DU), Sawangi (M), Wardha, Maharashtra, India-442001*

Received: 17th May, 2024; Revised: 15th July; 2024; Accepted: 01st August, 2024; Available Online: 31st August, 2024

ABSTRACT

Cardiovascular diseases (CVDs) are a major global health problem that cause a lot of illness, death, and high healthcare costs. As medical science advances, the number of people with CVDs continues to rise, necessitating the development of new methods for their prevention, diagnosis, and treatment. In recent years, using digital health technologies in cardiovascular care has become an excellent way to improve patient outcomes and make disease management better. It is possible for digitalis medicines, which come from the foxglove plant (*Digitalis purpurea*), to improve heart health in the digital age. In the field of cardiovascular medicine, this in-depth review looks at digitalis's historical importance, pharmacology, clinical uses, safety concerns, and digital transformation. The review starts with an overview of the epidemiological setting and the problems that CVDs cause, emphasizing the urgent need for creative solutions to deal with this worldwide health event. This article deals with how it has changed over time, from herbal remedies to modern drug therapy. It informs about the pharmacology of digitalis, mostly the way it works, its pharmacokinetics, and its pharmacodynamics. Pharmaceuticals that contain digitalis mainly work by stopping the Na+/K+ ATPase pump. The medication can help with heart failure, atrial fibrillation, and some types of arrhythmias. Digitalis's digital transformation is looked at with a focus on the way digital health technologies are used in its management, monitoring, and effectiveness. The review highlights that digitalis-based interventions could change the way cardiovascular medicine is done in the modern era.

Keywords: Atrial flutter, Digitalis purpurea, Dyslipidemia, Inotropic, Pharmacotherapy, Pediatric.

International Journal of Pharmaceutical Quality Assurance (2024); DOI: 10.25258/ijpqa.15.3.115

How to cite this article: Barole ND, Mude GS, Godde KP, Tenpe SV. Enhancing Cardiovascular Health with the Implementation of Digitalis. International Journal of Pharmaceutical Quality Assurance. 2024;15(3):1862-1871.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Superpowers found in the natural plant kingdom can treat and cure a wide range of human illnesses.[1] Cardiovascular diseases (CVDs) are a major public health problem around the world that puts a lot of stress on people, healthcare systems, and economies [2]. CVDs are still the leading cause of death in the world, killing millions of people every year; even though medical science and technology have come a long way, to address this serious health crisis, we need a multifaceted approach that incorporates prevention, early detection, and innovative treatment methods.[3] In recent years, adding digital health technologies to cardiovascular care has become a promising way to improve patient outcomes and make CVD management better.[4] There are many medications that can help with health problems, but digitalis, which comes from the foxglove plant (*Digitalis purpurea*), is getting more attention because it might help heart health in this digital age.[5] Herbal medicines are very popular all over the world because they have a wide range of biological and medical effects. Herbal medicines made from natural ingredients are good for you and help you stay healthy.[6]

This article begins by explaining the importance of digital interventions in addressing cardiovascular health problems. Furthermore, the article underscores the prevalence of cardiovascular diseases (CVDs) and their profound impact on individuals, underscoring the pressing necessity for efficacious interventions. Additionally, it delves into the progression of digitalis utilization in addressing heart conditions, tracing its development from traditional remedies to contemporary pharmaceuticals.7 It has changed because of advances in technology, which are talked about in the introduction. These changes have impacted the management, supervision, and overall performance of Digitalis.[8] A variety of things, such as changing lifestyles, less exercise, and new eating habits, have led to their emergence among the general population.9

Overview of Cardiovascular Diseases

Coronary artery disease, heart failure, arrhythmias, and hypertension represent various forms of cardiovascular diseases. Together, these conditions exert a significant impact on global health, contributing to premature mortality, diminished quality

**Author for Correspondence: barolenisha05@gmail.com*

of life, and substantial healthcare expenditures.[3] According to the World Health Organization (WHO), cardiovascular diseases (CVDs) account for approximately 17.9 million fatalities annually, representing roughly one-third of the global mortality rate. In the forthcoming decades, factors including population aging, poor dietary choices, sedentary lifestyles, and other modifiable risk elements are anticipated to fuel a surge in CVD prevalence.[10] Cardiovascular diseases (CVDs) not only affect individual health but also exert significant societal and economic ramifications, resulting in substantial direct healthcare expenditures, indirect productivity declines, and societal burdens.[11] In countries with high incomes, CVDs cost a lot of money for healthcare, which puts a strain on budgets and hurts efforts to achieve sustainable development. In low- and middle-income countries, where healthcare resources are often limited, CVDs can make health disparities worse and slow down efforts to provide health insurance to everyone.[12]

It takes a complete and unified approach that covers the whole range of care to deal with the many problems that CVDs cause.[13] Lifestyle changes (like avoiding smoking, eating healthier, and being more active) and risk factor management (like controlling high blood pressure and cholesterol) are important for lowering the risk of CVDs, but secondary and tertiary prevention strategies are just as important for people who already have cardiovascular conditions [14]. Innovative treatment methods that use technology have the potential to improve clinical outcomes and make care for patients better.[15]

Historical Significance of Digitalis

Since ancient times, people have used digitalis to treat heart problems. For example, historical records show that people in ancient civilizations used it to treat heart difficulties.[16] But it wasn't until the 18th century that digitalis became well-known in Western medicine. The groundbreaking work of English doctor William Withering made this possible [17]. "An Account of the Foxglove and Some of Its Medical Uses," which Withering wrote and published in 1785, was a major turning point in the history of cardiovascular therapy. Withering described in this significant paper the benefits of foxglove extracts for individuals suffering from dropsy, an edema resulting from congestive heart failure [18]. Through carefully documenting case studies and clinical outcomes, Withering provided strong proof of digitalis's therapeutic potential in easing symptoms and improving heart function.[19]

It became a standard part of medical practice after Withering's study became widely known in the medical community. A few years later, pharmacological studies demonstrated how digitalis' cardiovascular effects work, which made it possible to create standard formulations and dosage routines.[20] Digoxin and other digitalis preparations treated heart failure, atrial fibrillation, and other heart problems for a long time in the 19th and 20th centuries.[21] Since the beginning of time, plants have had a significant impact on culture, thought, and the economy. India is basically a global herbarium, even though plants and herbs are the main source of medicine there.[22]



Figure 1: Foxglove plant (*Digitalis purpurea*)

The Digital Transformation of Digitalis

While the healing properties of digitalis are still based on hundreds of years of botanical knowledge, the digital age has brought about a new era of innovation and opportunity in heart care.[23] Although the therapeutic attributes of digitalis remain grounded in centuries-old botanical wisdom, the advent of the digital age has ushered in a fresh era of innovation and potential in cardiac healthcare.[24] Even though the world has a lot of health problems, there are a lot of customer testimonials, and success stories that prove natural therapies work.[25]

The integration of digital health with cardiovascular medicine holds promise for markedly enhancing patient outcomes and revolutionizing care delivery. Remote patient monitoring platforms, wearable technology, mobile applications, and telehealth solutions enable both patients and healthcare providers to monitor vital signs, ensure adherence to medication regimens, and facilitate timely interventions [26]. By using real-time data and analytics, healthcare professionals can spot changes in patients' conditions before they happen, make treatment plans more effective, and lower the risk of bad outcomes [27]. Digital interventions have the potential to revolutionize cardiovascular care in the twenty-first century by aiding in risk assessment, treatment decision-making, patient involvement, and adherence reinforcement [28].

The utilization of technology has brought about significant transformations in the management of cardiovascular diseases, offering novel avenues to enhance patient outcomes, optimize clinical workflows, and deepen understanding of the field [4]. Harnessing the capabilities of digitalis and technology, healthcare practitioners can address the complex challenges posed by cardiovascular diseases by embracing the principles of digital health and personalized medicine. Leveraging digitalis to its fullest extent, they can enhance cardiovascular health and overall well-being globally through collaborative research, innovation, and education.[29]

Need for Innovative Interventions

Despite advancements in medical science and technology, CVDs remain the foremost cause of illness and mortality

globally, posing substantial financial burdens on individuals, families, healthcare systems, and economies.[30]

Epidemiological Landscape

Heart diseases kill about 17.9 million people a year, or about one-third of all deaths in the world, according to the World Health Organization (WHO).[2] Different parts of the world have different rates of CVDs, and low- and middle-income countries have a disproportionately high disease burden. CVDs affect not only death but also lead to various other problems such as reduced quality of life, impaired function, and disparities in wealth.[12]

Rising Risk Factors

Some risk factors that can influence the development and progression of CVDs include hypertension, dyslipidemia, diabetes mellitus, obesity, smoking, physical inactivity, bad eating habits, genetic predisposition, and socioeconomic factors. Cities, factories, globalization, changes in population, lifestyles, and environmental factors are all making these risk factors more common around the world.[31]

Limitations of Conventional Approaches

Traditional methods of heart disease prevention and treatment have made great strides in the last few decades, but they are not perfect. Pharmacotherapy, behavioral changes, and surgeries are necessary for managing CVDs, but they might not be sufficient or the most effective due to the disease's complex nature. Also, some groups might not be able to get to, afford, or use current interventions; this is especially true for those who live in places with few resources or in communities that aren't getting enough help.[32]

Challenges in Healthcare Delivery

Numerous issues affect cardiovascular care, including unequal access to services, flawed care delivery models, inefficient healthcare systems, insufficient infrastructure and human resources, patients who lack involvement or empowerment, and a failure to adhere to evidence-based guidelines. These issues make it harder to provide timely, fair, and patient-centered care, which worsens health disparities and keeps the disease burden going [33].

Emergence of Innovative Interventions

Due to these problems, more and more people realize that we need new ways to deal with the causes of CVDs, make treatments work better, and boost the health of the whole population [4]. Innovative interventions include a wide range of methods, from new medicines and medical gadgets to digital health technologies, strategies for precision medicine, and public health projects, these interventions transform the delivery of cardiovascular care by utilizing cutting-edge technology, science, and collaboration across various fields [34].

The Promise of Digital Health

Digital health includes many different types of tools and platforms, such as smartwatches, mobile apps, telemedicine, remote monitoring systems, electronic health records, AI, and big data analytics.[35] These technologies could transform the delivery of cardiovascular care in a number of ways, including more early detection, improved risk stratification, better treatment choices, personalized medicine, patient engagement, self-management, and more efficient healthcare delivery.[36] Development can help to improve events, quality of life, and the social and economic effects of CVDs by taking a more comprehensive and multidisciplinary approach to care across the entire healthcare range.[3]

Historical Perspective of Digitalis

This medication has been around for hundreds of years, demonstrating how medical knowledge has changed over time and how humans have always tried to find better ways to treat heart problems. Digitalis has a history that goes back to ancient herbal medicines, its journey includes botanical knowledge, real-world observations, and scientific inquiry, which end with its modern pharmaceutical uses.[16]

Early Origins

The history of digitalis began when ancient healers and herbalists discovered the medicinal potential of plants like the foxglove (*Digitalis purpurea*). A lot of old texts and folklore talk about the fact that the foxglove is believed to be good for healing, especially for edema, dropsy, and heart problems. The exact ways that the foxglove worked were not known, but the fact that it worked in real life led to its use in traditional medicine.[37]

William Withering and the Dawn of Modern Medicine

In the late 18th century, English physician William Withering did remarkable work that changed the course of digitalis history. Withering's significant effort, "An Account of the Foxglove and Some of Its Medical Uses," came out in 1785. It was a record of his observations and experiences with digitalis therapy. Drawing on his experiences with people who had dropsy, Withering wrote about how to use foxglove preparations, their effects, and their results. This enhanced our comprehension of their potential medicinal applications. [17,18] Digitalis is effective in treating heart failure and edema, and his work inspired many doctors and scientists to learn more about its pharmacological properties.[20]

Pharmacological Insights

In the decades that followed, there was a lot of drug research trying to figure out what digitalis was, scientists wanted to find out what the active parts of the foxglove plant were, what effects they had on the body, and how to better extract and standardize digitalis preparations. Discovering cardiac glycosides, especially digoxin and digitoxin, as the main bioactive compounds in digitalis that cause its therapeutic effects was one of the most important findings.[38]

Therapeutic Advancements

As research teams learned more about digitalis' pharmacology, they started to use its heart-healthy effects to treat a range of heart problems.[39] With its ability to relieve symptoms, support blood flow, and improve patient outcomes, the plant has become an important treatment for heart failure, atrial fibrillation, and other arrhythmias.[40]

Evolving Perspectives and Challenges

Worries about side effects, limited effectiveness, drug interactions, and individual differences prompted doctors to be cautious and closely monitor patients taking digitalis, changes in clinical practice, progress in drug therapy, and the rise of new treatments have all led to a reevaluation of digitalis' role in CVDs.[41] The development of digitalis over time shows how tradition and innovation, folklore and science, empiricism, and evidence have all happened together. From its humble beginnings as a folk remedy to its status as a key therapy in modern medicine, digitalis has come a long way thanks to people's creativity, curiosity, and persistence, considering its history, we gain a better understanding of digitalis's lasting impact on cardiovascular medicine.[42]

Early Discoveries and Traditional use

Herbalists and caregivers from ancient civilizations used plants like the foxglove (Digitalis purpurea) to treat illness. For many years, people in ancient Greece and Rome believed that the foxglove could heal illnesses, especially those related to the heart, there are many references in history and folklore to using foxglove preparations to help with edema, dropsy, and other heart problems.[37] Although early herbalists didn't know the exact way the foxglove worked, they knew that it worked, which led to its traditional use in herbal medicines.[43] To treat a wide range of illnesses, foxglove extracts were often given orally or topically in the form of teas, tinctures, poultices, or ointments. Although scientists don't fully understand foxglove, its long history of use in traditional medicine shows that it is still a popular plant for treating heart problems.[44]

Evolution of Digitalis in Medicine

Withering's treatise was a turning point in digitalis history; it evolved from a folk remedy into a medicine based on evidence. His careful writing and organized method gave us scientific proof that digitalis could help treat heart failure and other related conditions. In addition to demonstrating the effectiveness of digitalis, Withering's work paved the way for additional drug studies to understand its mechanism of action and potential therapeutic uses.[18] Important discoveries included finding that cardiac glycosides, such as digoxin and digitoxin, are the main bioactive compounds in digitalis that cause its cardiovascular effects.[16] These potent compounds, derived from the foxglove plant, exerted profound effects on cardiac function, enhancing myocardial contractility, reducing heart rate, and modulating cardiac rhythm.[23] After learning more about digitalis' pharmacological properties, clinicians began using it in regular medicine, revolutionizing the treatment of cardiovascular diseases.[45] Ancient knowledge, real-world observations, and scientific inquiry have all contributed to the development of digitalis in medicine. As a simple traditional medicine, digitalis has come a long way. It has been shaped by people's creativity, curiosity, and determination, and modern pharmaceutical therapy now uses it.[16]

Pharmacology of Digitalis

The basic science behind digitalis is based on its main active ingredients, cardiac glycosides, which have very strong effects on the cardiovascular system. To get the most out of digitalis for treating a range of heart conditions, it is important to understand its pharmacokinetics, mechanisms of action, and therapeutic implications.[23]

Chemical Composition and Structure

In digitalis preparations, active ingredients are used. Glycosides are steroid-like chemicals made up of a steroid center and a sugar ring [5]. It's easier for cardiac glycosides to interact with cell receptors and ion channels in heart tissues because their structures are similar to those of endogenous steroids. This is what produces their pharmacological effects.[46]

Mechanisms of Action

Digitalis primarily functions as a drug by inhibiting the sodium-potassium adenosine triphosphatase (Na+/K+ ATPase) pump, a crucial membrane-bound enzyme presents in myocardial cells. It raises the concentration of sodium inside cells by blocking the Na+/K+ ATPase pump, which in turn lowers the activity of the sodium-calcium exchanger (NCX) on the cell membrane, this causes calcium ions to build up inside cells, which improves the heart's ability to contract and pump blood.[47]

Inhibition of Na+/K+- ATPase pump

When digitalis compounds bind to the alpha subunit of the Na+/K+ ATPase pump, it stops working. A decrease in the activity of the Na+/Ca2+ exchanger causes sodium ions ([Na+] i) to accumulate inside cells, while calcium ions ([Ca2+]i) rise. Increasing [Ca2+]i makes the heart muscle contract stronger by helping calcium leave the sarcoplasmic reticulum during excitation-contraction coupling.[48]

Positive inotropic effect

The main chemical effect of digitalis on the heart is its positive inotropic effect, which means that it makes the heart muscle contract more strongly. For better cardiac output and stroke volume, digitalis strengthens myocardial contraction by raising calcium levels inside cells, when heart muscle function is poor, like in heart failure, this effect is especially helpful.[49]

Negative chronotropic effect

It has both a positive inotropic effect and a negative chronotropic effect, which means it slows down the heart rate,



Figure 2: Mechanism of digoxin action

stimulates the vagus nerve, and blocks sympathetic activity, causing this effect. This lowers the rate at which the sinoatrial node fires and the speed at which atrioventricular conduction occurs. Because of this, digitalis can help control heart rate in conditions like atrial fibrillation and atrial flutter.[50]

Enhanced baroreceptor sensitivity

It has been shown that digitalis raises the sensitivity of baroreceptors, which helps keep blood pressure and heart health in check and may help keep blood flow stable and stop heart rhythm problems by changing the way baroreceptors work.[51]

Pharmacokinetics and Pharmacodynamics

When taken orally, digitalis glycosides enter the digestive system and undergo extensive first-pass metabolism in the liver. Ordinary digoxin has a bioavailability of about 60–80%, but digitoxin has a higher bioavailability because it dissolves better in fats. Due to their half-lives of 30-40 hours, digoxin and digitoxin require careful dosage and monitoring to prevent accumulation and toxicity.[52] Digitalis has beneficial inotropic effects on the heart when taken in the right amount, but when taken in excess, it can be toxic [23]. Digoxin's therapeutic range is small, usually between 0.5 and 2 nanograms per milliliter (ng/mL), but the best dose for each patient may be different. Monitoring serum digoxin levels is crucial for ensuring the effectiveness of the treatment and reducing the likelihood of side effects.[53]

Clinical Applications

It improves symptoms, lowers hospitalizations, and raises exercise tolerance in people with heart failure by changing neurohormonal pathways and making the heart contract more. Digitalis, as a treatment for atrial fibrillation, helps keep the heart rate under control and may help some patients switch to sinus rhythm [54].

Safety Considerations

These digitalis medicines can be beneficial, but they can also be harmful if taken in large doses, by individuals with kidney disease, electrolyte imbalances, or concurrently with other medications.[41] Digitalis poisoning can cause problems with the digestive system (like nausea, vomiting, and loss of appetite), the heart (like atrial and ventricular tachyarrhythmias), and the brain and eyes (like confusion and problems seeing).[55] The substance's pharmacology includes its mechanism of action, movement within the body, alteration of effects, application in medicine, and safety. The medicines usually work by blocking the Na+/K+ ATPase pump. This makes the heart muscle contract stronger and changes the way the heart's electrical system works. 56 Digitalis medications, proven effective in treating heart failure and arrhythmias, require careful dosing, monitoring, and selection for each patient to achieve optimal results and minimize the risk of side effects. Doctors treating heart disease patients must possess a comprehensive understanding of digitalis pharmacology to ensure the safe and effective use of these drugs in clinical settings.[23,41]

Clinical Applications of Digitalis

The foxglove plant yields digitalis, a long-used remedy for a variety of heart issues. For instance, its useful pharmacological properties enable its use in treating heart failure and irregular heartbeats. For healthcare professionals to provide the best care to their patients, they need to know how to use it clinically.[57]

Treatment of Heart Failure

Individuals with heart failure, a long-term condition in which the heart can't pump blood efficiently, often take digitalis, especially digoxin. By increasing myocardial contractility and changing neurohormonal pathways, digitalis improves heart failure symptoms, lowers hospitalizations, and raises exercise tolerance.[58] It achieves this by blocking the sodium-potassium adenosine triphosphatase (Na+/K+ ATPase) pump. This raises the level of calcium inside cells and makes the heart contract stronger. Digitalis also widens blood vessels and controls sympathetic activity, which helps people with heart failure even more.[59]

Control of Atrial Fibrillation

Digitalis plays a crucial role in treating atrial fibrillation (AF), a common long-term heart rhythm problem characterized by fast, irregular electrical activity in the atria. Digitalis lowers the heart rate of people with AF by slowing down the conduction between the atria and ventricles, as well as the rate at which the ventricles respond.[60] The antiarrhythmic effects of digitalis increase vagal tone and decrease sympathetic activity. This makes it a useful addition to rate control strategies for managing AF. It helps a lot for people with fast ventricular rates who can't have their rhythm controlled or need rate control before cardioversion.[61]

Management of Atrial Flutter

Digitalis treats atrial flutter, a supraventricular tachyarrhythmia. Organized atrial activity and a fast, regular atrial rate are its hallmarks.[62] It is similar to AF in that it slows atrioventricular conduction and lowers ventricular response rates.[63] By changing the conduction of atrioventricular nodes and improving vagal tone, digitalis helps patients with atrial flutter keep their heart rate stable and improve their hemodynamic stability.[64]

Role in Certain Arrhythmias

Beyond AF and atrial flutter, digitalis can treat other heart rhythm issues. These include atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentrant tachycardia (AVRT). Due to its ability to change atrioventricular node conduction and improve vagal tone, digitalis can help slow down the heart rate and help it return to a normal rhythm [65]. Although digitalis isn't typically the first treatment for these arrhythmias, some patients may use it in conjunction with other antiarrhythmic medications or catheter ablation procedures.[66]

Digitalis medications, especially digoxin, play a crucial role in treating heart problems such as heart failure, atrial fibrillation, atrial flutter, and some arrhythmias [67]. As a result

of improving myocardial contractility, changing cardiac electrophysiology, and stopping arrhythmic activity, digitalis makes cardiovascular disease symptoms better, lowers hospitalizations, and raises the quality of life for patients [68]. A complete knowledge of digitalis' clinical uses is essential for healthcare professionals taking care of heart patients, as it ensures the safe and effective use of these drugs in real life [69].

Consideration and Monitoring of Digitalis on Cardiovascular

"Consideration and monitoring" in digitalis therapy refers to closely assessing and monitoring patients receiving digitalis medications such as digoxin [41]. There are a few things doctors have to check before starting digitalis therapy to make sure it is the best choice for each patient [70]. Additionally, it is important to look at the patient's medical history, heart health, medications they are taking, kidney function, electrolyte levels, and any possible risk factors for digitalis toxicity. It is also necessary to think about the pros and cons of digitalis therapy and any other treatments that might work better for the patient's condition.[41]

Once digitalis therapy starts, it needs to be closely watched to see how well it's working, spot early signs of toxicity, and make any necessary changes to the therapy, regular checks of clinical symptoms, vital signs, serum digoxin levels, electrolyte levels (especially potassium and magnesium), renal function, and cardiac rhythm (via electrocardiography) may be part of monitoring. Close monitoring lets doctors find the best way to use digitalis, change the dose, and act quickly if any side effects or toxicity happen.[71]

Narrow Therapeutic Index

A drug with a "narrow therapeutic index" (NTI) has a small difference between the lowest dose that works and the lowest dose that is harmful. Drugs with a narrow therapeutic index need to be carefully dosed and watched to make sure that patients get the right amount of medicine to work without getting sick or having side effects.[72] Pharmaceuticals with a narrow therapeutic index include digoxin and other digitalis compounds. The pharmacological effects of these drugs happen at fairly low doses, but even small breaks from the therapeutic range can be harmful. Dosing and monitoring digitalis can be made more difficult by things like age, kidney function, taking other medicines at the same time, and electrolyte imbalances.[73]



Figure 3: Consideration and monitoring of digitalis

Electrolyte Imbalance Risk

Elevated electrolyte levels are a major concern when digitalis therapy is prescribed in cardiovascular medicine, and changing the levels of electrolytes like calcium, magnesium, and potassium can affect the ways digitalis works in the body, which could make it more toxic or less effective as a medicine.[74]

Hypokalemia

Digitalis is more likely to harm the heart when there is insufficient potassium in the blood. Although low potassium levels can strengthen the effects of digitalis on heart conduction, they can also increase the risk of arrhythmias, including tachycardia and fibrillation, which can be life-threatening ventricular arrhythmias. Digitalis users should have their blood potassium levels checked frequently because they don't get sick easily and individuals with low potassium levels require immediate treatment.[75]

Hypomagnesemia

The heart needs magnesium to maintain its rhythm and ability to contract normally. As a person who already doesn't have enough magnesium, digitalis is more likely to make a person's symptoms worse. Enhancing the treatment of people with hypomagnesemia could improve the effectiveness of digitalis and reduce the risk of heart problems, particularly when potassium levels are also low.[76]

Hypercalcemia

Digitalis use may make heart problems worse for people whose blood calcium levels are already high, such as cardiac arrhythmias or myocardial damage. People taking digitalis should carefully monitor their blood calcium levels, especially if they have a condition like hyperparathyroidism that makes them more likely to have high calcium levels.[77]

Hyponatremia

Low sodium levels that cause anemia can sometimes affect digitalis's function and metabolism. With lower blood sodium levels, the body may change how it distributes and gets rid of digitalis, which could increase the risk of toxicity. Users consuming digitalis need to be closely watched, especially those who are likely to develop hyponatremia, like those with heart failure or syndrome of inappropriate antidiuretic hormone secretion (SIADH).[78]

Digitalis in Special Populations

Digoxin and other digitalis medicines can treat a variety of heart problems. Digitalis therapy may need extra care for older patients, children, people with kidney problems, and women who are pregnant or breastfeeding.[69]

Elderly Patients

Older people are more likely to suffer from cardiac conditions

like heart failure and atrial fibrillation, which is why they frequently receive digitalis medications. Aging-related changes in pharmacokinetics and pharmacodynamics may make older adults more likely to become toxic to digitalis.[79] Lower kidney function, changes in drug metabolism, and a higher sensitivity to drug effects may make it more likely for older people who are taking digitalis to have bad reactions. Monitoring serum digoxin levels and kidney function is crucial to reduce the risk of toxicity in this vulnerable group of individuals.[80]

Pediatric Populations

Kids don't use these medications very often because there isn't much evidence that they are safe and effective for them. Pediatric patients have been given digoxin to treat some congenital heart defects and arrhythmias, but their dosing schedules and therapeutic monitoring may be different from those used with adults.[81] Children may need different doses depending on their age, weight, and health, and it's important to be aware of any possible drug interactions or side effects. There needs to be more research done to find out if digitalis therapy is safe and effective for kids.[82]

Patients with Renal Impairment

Regularly checking renal function and changing digoxin doses based on the estimated glomerular filtration rate (eGFR) are important steps in preventing drug buildup and toxicity.[83] Patients with moderate to severe renal impairment may require lower initial doses and longer intervals between doses. It is critical to keep track of these patients' digoxin levels and kidney function in order to ensure safe and effective treatment.[84]

Pregnant or Breastfeeding Women

Drugs that contain digitalis should be used with care by women who are pregnant or breastfeeding since they can pass through the placenta and be found in breast milk. Digoxin is generally thought to be safe to use during pregnancy, but it should only be done when the possible benefits are greater than the risks to the unborn child.[85] Close monitoring of maternal and fetal well-being is recommended during pregnancy, with consideration of alternative therapies when possible. In breastfeeding women, digoxin exposure to the infant through breast milk is minimal, but monitoring for signs of toxicity in the infant is advised.[86] Special considerations may be required when prescribing digitalis drugs to older people, children, people with kidney problems, and pregnant or breastfeeding women.[87] Adequate risk-benefit analysis, personalized dosing, close monitoring of serum digoxin levels and renal function, and ongoing evaluation of these factors are necessary to make sure that therapy is safe and effective for these groups. Weigh the potential benefits of digitalis therapy against the risks of side effects, and consider other treatment options if necessary.[41]

CONCLUSION

In summary, a thorough examination of digitalis drugs in cardiovascular health underscores their enduring significance, particularly in the digital era. From their origins as herbal remedies to their integration into contemporary drug therapies, digitalis medications have played a crucial role in managing various heart conditions such as heart failure, atrial fibrillation, and certain arrhythmias by inhibiting the Na+/K+ ATPase pump. However, it is imperative for the creators of digitalis to prioritize safety considerations, including risks of harm and potential drug interactions, before widespread adoption in clinical settings. The digitization of digitalis has revolutionized cardiac care, leveraging advanced technology and data-driven methodologies. Wearable devices, telehealth platforms, and digital drug delivery systems offer promising avenues for enhancing treatment outcomes and patient engagement.

Moreover, advancements in data analytics, predictive modeling, and precision medicine facilitate tailored interventions, improving risk assessment, treatment selection, and adherence. Looking ahead, the field is poised for further innovation in digitalis therapy within cardiovascular medicine. Collaboration among researchers, policymakers, and practitioners is essential to maximize the benefits of digital interventions for combating heart diseases. Through evidence-based practices, personalized medicine approaches, and integration of digital health solutions, healthcare professionals can collectively strive to enhance cardiovascular outcomes, mitigate care disparities, and alleviate the global burden of CVDs. In essence, digitalis medications represent a pivotal component of heart therapy, bridging traditional and contemporary approaches to empower physicians in delivering personalized, efficient, and equitable care to patients worldwide. While the landscape of cardiovascular medicine continues to evolve, healthcare providers can navigate this dynamic terrain with confidence, leveraging technology, data insights, and collaborative efforts to optimize patient care.

REFERENCES

1. Vaidya S. Nutritional and health benefits of kiwifruit: An overview. Annals of Phytomedicine: An International Journal [Internet]. [cited 2024 May 14]; Available from: https://www.academia.edu/107615976/Nutritional_and_health_benefits_of_kiwifruit_An_overview
2. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76:2982–3021.
3. Ullah A, Kumar M, Sayyar M, Sapna F, John C, Memon S, et al. Revolutionizing Cardiac Care: A Comprehensive Narrative Review of Cardiac Rehabilitation and the Evolution of Cardiovascular Medicine. Cureus. 15:e46469.
4. Santo K, Redfern J. Digital Health Innovations to Improve Cardiovascular Disease Care. Curr Atheroscler Rep. 2020;22:71.
5. Kumavath R, Paul S, Pavithran H, Paul MK, Ghosh P, Barh D, et al. Emergence of Cardiac Glycosides as Potential Drugs: Current and Future Scope for Cancer Therapeutics. Biomolecules. 2021;11:1275.
6. Lote S, Agrawal S, Khobragade D, Pethe A. Phytopharmacological investigation on Lawsonia inermis L.: A comprehensive review. ap [Internet]. 2023 [cited 2024 May 14];12. Available from: http://www.ukaazpublications.com/publications/?smd_process_

download=1&download_id=10702
7. Zwack CC, Haghani M, Hollings M, Zhang L, Gauci S, Gallagher R, et al. The evolution of digital health technologies in cardiovascular disease research. NPJ Digit Med. 2023;6:1.
8. Wang RC, Wang Z. Precision Medicine: Disease Subtyping and Tailored Treatment. Cancers (Basel). 2023;15:3837.
9. Shastrakar P, Tapre DN, Kallewar NG, Jain SP, Borikar SP. Hypoglycemic activity of combined dried powder of Andrographis paniculata (Burm.) Nees whole plant and Gymnema sylvestre R. Br. leaves in experimental rat model. ap [Internet]. 2023 [cited 2024 May 15];12. Available from: http://www.ukaazpublications.com/publications/?smd_process_download=1&download_id=10634
10. Luo Y, Liu J, Zeng J, Pan H. Global burden of cardiovascular diseases attributed to low physical activity: An analysis of 204 countries and territories between 1990 and 2019. Am J Prev Cardiol. 2024;17:100633.
11. Reil JC, Böhm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol. 2007;96:585–92.
12. Wurie HR, Cappuccio FP. Cardiovascular disease in low- and middle-income countries: an urgent priority. Ethn Health. 2012;17:543–50.
13. Karwalajtys T, Kaczorowski J. An integrated approach to preventing cardiovascular disease: community-based approaches, health system initiatives, and public health policy. Risk Manag Healthc Policy. 2010;3:39–48.
14. Rippe JM. Lifestyle Strategies for Risk Factor Reduction, Prevention, and Treatment of Cardiovascular Disease. Am J Lifestyle Med. 2018;13:204–12.
15. Bekbolatova M, Mayer J, Ong CW, Toma M. Transformative Potential of AI in Healthcare: Definitions, Applications, and Navigating the Ethical Landscape and Public Perspectives. Healthcare (Basel). 2024;12:125.
16. Whayne TF. Clinical Use of Digitalis: A State of the Art Review. Am J Cardiovasc Drugs. 2018;18:427–40.
17. Friend DG. Digitalis after two centuries (William Withering). Arch Surg. 1976;111:14–9.
18. Tröhler U. Withering's 1785 appeal for caution when reporting on a new medicine. J R Soc Med. 2007;100:155–6.
19. Gona SR, Rosenberg J, Fyffe-Freil RC, Kozakiewicz JM, Money ME. Review: Failure of current digoxin monitoring for toxicity: new monitoring recommendations to maintain therapeutic levels for efficacy. Front Cardiovasc Med. 2023;10:1179892.
20. Bessen HA. Therapeutic and toxic effects of digitalis: William Withering, 1785. J Emerg Med. 1986;4:243–8.
21. Virgadamo S, Charnigo R, Darrat Y, Morales G, Elayi CS. Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World J Cardiol. 2015;7:808–16.
22. Telrandhe U, Gunde M. Phytochemistry, pharmacology and multifarious activity of Cassia tora L.: A comprehensive review. Annals of Phytomedicine: An International Journal. 2022;11.
23. Khandelwal R, Vagha JD, Meshram RJ, Patel A. A Comprehensive Review on Unveiling the Journey of Digoxin: Past, Present, and Future Perspectives. Cureus. 2024;16:e56755.
24. Yeung AWK, Torkamani A, Butte AJ, Glicksberg BS, Schuller B, Rodriguez B, et al. The promise of digital healthcare technologies. Front Public Health. 2023;11:1196596.
25. Mude G, Malviya V, Singune S, Mude S. Exploration and treatment of salt-induced hyperlipidemia, adiposity and renal dysfunction by utilizing of Matricaria recutita L. whole plant concentrate in wistar rat model. ap [Internet]. 2023 [cited 2024 May 15];12. Available from: http://www.ukaazpublications.com/publications/?smd_process_download=1&download_id=10638
26. Ahmed SK, Hussein S, Chandran D, Islam MdR, Dhama K. The role of digital health in revolutionizing healthcare delivery and improving health outcomes in conflict zones. Digit Health. 2023;9:20552076231218158.
27. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ. 2023;23:689.
28. Redfern J, Coorey G, Mulley J, Scaria A, Neubeck L, Hafiz N, et al. A digital health intervention for cardiovascular disease management in primary care (CONNECT) randomized controlled trial. NPJ Digit Med. 2020;3:117.
29. Azizi Z, Adedinsewo D, Rodriguez F, Lewey J, Merchant RM, Brewer LC. Leveraging Digital Health to Improve the Cardiovascular Health of Women. Curr Cardiovasc Risk Rep. 2023;17:205–14.
30. Mendis S, Graham I, Narula J. Addressing the Global Burden of Cardiovascular Diseases; Need for Scalable and Sustainable Frameworks. Glob Heart. 17:48.
31. Bays HE, Taub PR, Epstein E, Michos ED, Ferraro RA, Bailey AL, et al. Ten things to know about ten cardiovascular disease risk factors. Am J Prev Cardiol. 2021;5:100149.
32. Zaree A, Dev S, Yaseen Khan I, Arain M, Rasool S, Khalid Rana MA, et al. Cardiac Rehabilitation in the Modern Era: Optimizing Recovery and Reducing Recurrence. Cureus. 15:e46006.
33. Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. Lancet Glob Health. 2018;6:e1196–252.
34. Kasoju N, Remya NS, Sasi R, Sujesh S, Soman B, Kesavadas C, et al. Digital health: trends, opportunities and challenges in medical devices, pharma and bio-technology. CSI Transactions on ICT. 2023;11:11–30.
35. Maddula R, MacLeod J, McLeish T, Painter S, Steward A, Berman G, et al. The role of digital health in the cardiovascular learning healthcare system. Front Cardiovasc Med. 2022;9:1008575.
36. Sachdeva P, Kaur K, Fatima S, Mahak F, Noman M, Siddenthi SM, et al. Advancements in Myocardial Infarction Management: Exploring Novel Approaches and Strategies. Cureus. 15:e45578.
37. Norn S, Kruse PR. [Cardiac glycosides: From ancient history through Withering's foxglove to endogeneous cardiac glycosides]. Dan Medicinhist Arbog. 2004;119–32.
38. Okita GT. Pharmacology of digitalis. Pediatr Clin North Am. 1964;11:229–45.
39. Ramalhão C. [Role of digitalis in the pharmacologic treatment of cardiac insufficiency]. Rev Port Cardiol. 1989;8:469.
40. Hood WB, Dans AL, Guyatt GH, Jaeschke R, McMurray JJV. Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database Syst Rev. 2014;2014:CD002901.
41. Andrews P, Anseeuw K, Kotecha D, Lapostolle F, Thanacoody R. Diagnosis and practical management of digoxin toxicity: a narrative review and consensus. Eur J Emerg Med. 2023;30:395–401.
42. Wade OL. Digoxin 1785-1985. I. Two hundred years of digitalis. J Clin Hosp Pharm. 1986;11:3–9.
43. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder

T, Wawrosch C, Uhrin P, et al. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv. 2015;33:1582–614.
44. Lehmann A, Späni S, Harings-Kaim A, Probst C, Christ A, Leuppi-Taegtmeyer AB. A case of intoxication with tea made from Digitalis purpurea. Glob Cardiol Sci Pract. 2021:e202102.
45. Kulick DL, Rahimtoola SH. Current role of digitalis therapy in patients with congestive heart failure. JAMA. 1991;265:2995–7.
46. Ogazon del Toro A, Jimenez L, Hinojosa L, Martínez-Rendón J, Castillo A, Cereijido M, et al. Influence of Endogenous Cardiac Glycosides, Digoxin, and Marinobufagenin in the Physiology of Epithelial Cells. Cardiol Res Pract. 2019;2019:8646787.
47. Askari A. The sodium pump and digitalis drugs: Dogmas and fallacies. Pharmacol Res Perspect. 2019;7:e00505.
48. Terracciano CMN. Rapid inhibition of the Na+-K+ pump affects Na+-Ca2+ exchanger-mediated relaxation in rabbit ventricular myocytes. J Physiol. 2001;533:165–73.
49. Smith TW. The basic mechanism of inotropic action of digitalis glycosides. J Pharmacol. 1984;15 Suppl 1:35–51.
50. Coiado OC, Buiochi EB, William D. O'Brien J. Ultrasound-Induced Heart Rate Decrease: Role of the Vagus Nerve. IEEE transactions on ultrasonics, ferroelectrics, and frequency control. 2015;62:329.
51. Ferrari A, Gregorini L, Ferrari MC, Preti L, Mancia G. Digitalis and baroreceptor reflexes in man. Circulation. 1981;63:279–85.
52. Gerson CD, Lowe EH, Lindenbaum J. Bioavailability of digoxin tablets in patients with gastrointestinal dysfunction. Am J Med. 1980;69:43–9.
53. Goldberger ZD, Goldberger AL. Therapeutic Ranges of Serum Digoxin Concentrations in Patients With Heart Failure. Am J Cardiol. 2012;109:1818–21.
54. Gerakaris A, Mulita F, Koniari I, Artopoulou E, Mplani V, Tsigkas G, et al. Digoxin Impact on Heart Failure Patients with Atrial Fibrillation. Med Arch. 2022;76:23–8.
55. Chung EK. Digitalis intoxication. Postgrad Med J. 1972;48:163–79.
56. Katz AM. Effects of digitalis on cell biochemistry: sodium pump inhibition. J Am Coll Cardiol. 1985;5:16A-21A.
57. Jamshed F, Dashti F, Ouyang X, Mehal WZ, Banini BA. New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders. World J Gastroenterol. 2023;29:1824–37.
58. Ambrosy AP, Butler J, Ahmed A, Vaduganathan M, van Veldhuisen DJ, Colucci WS, et al. The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol. 2014;63:1823–32.
59. Tian J, Xie Z jian. The Na/K-ATPase and Calcium Signaling Microdomains. Physiology (Bethesda). 2008;23:205–11.
60. Arrigo M, Bettex D, Rudiger A. Management of Atrial Fibrillation in Critically Ill Patients. Crit Care Res Pract. 2014;2014:840615.
61. Geng M, Lin A, Nguyen TP. Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms. Front Pharmacol. 2020;11:581837.
62. Buttà C, Tuttolomondo A, Di Raimondo D, Milio G, Miceli S, Attanzio MT, et al. The supraventricular tachycardias: Proposal of a diagnostic algorithm for the narrow complex tachycardias. Journal of Cardiology. 2013;61:247–55.
63. Meijler FL. An "account" of digitalis and atrial fibrillation. J Am Coll Cardiol. 1985;5:60A-68A.
64. Carbucicchio C, Tondo C, Fassini G, Riva S, Agostoni P, Galli C, et al. Modulation of the atrioventricular node conduction to achieve rate control in patients with atrial fibrillation: long-term results. Pacing Clin Electrophysiol. 1999;22:442–52.
65. Wasmer K, Eckardt L, Baumgartner H, Köbe J. Therapy of supraventricular and ventricular arrhythmias in adults with congenital heart disease—narrative review. Cardiovasc Diagn Ther. 2021;11:550–62.
66. Könemann H, Güler-Eren S, Ellermann C, Frommeyer G, Eckardt L. Antiarrhythmic Treatment in Heart Failure. Curr Heart Fail Rep. 2024;21:22–32.
67. Maury P, Rollin A, Galinier M, Juillière Y. Role of digoxin in controlling the ventricular rate during atrial fibrillation: a systematic review and a rethinking. Research Reports in Clinical Cardiology. 2014;5:93–101.
68. Williams ES, Viswanathan MN. Current and Emerging Antiarrhythmic Drug Therapy for Ventricular Tachycardia. Cardiol Ther. 2013;2:27–46.
69. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. Circulation. 2006;113:2556–64.
70. Rahimtoola SH. Digitalis Therapy for Patients in Clinical Heart Failure. Circulation. 2004;109:2942–6.
71. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol. 1992;69:108G-118G; disc. 118G-119G.
72. Tamargo J, Le Heuzey JY, Mabo P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol. 2015;71:549–67.
73. Mar PL, Horbal P, Chung MK, Dukes JW, Ezekowitz M, Lakkireddy D, et al. Drug Interactions Affecting Antiarrhythmic Drug Use. Circulation: Arrhythmia and Electrophysiology. 2022;15:e007955.
74. Sundar S, Burma DP, Vaish SK. Digoxin toxicity and electrolytes: a correlative study. Acta Cardiol. 1983;38:115–23.
75. Osadchii OE. Mechanisms of hypokalemia-induced ventricular arrhythmogenicity. Fundamental & Clinical Pharmacology. 2010;24:547–59.
76. Adamopoulos C, Pitt B, Sui X, Love TE, Zannad F, Ahmed A. Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. Int J Cardiol. 2009;136:270–7.
77. Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med. 2011;40:41–6.
78. Mansoor F, Bai P, Kaur N, Sultan S, Sharma S, Dilip A, et al. Evaluation of Serum Electrolyte Levels in Patients With Anemia. Cureus. 13:e18417.
79. Wofford JL, Ettinger WH. Risk factors and manifestations of digoxin toxicity in the elderly. Am J Emerg Med. 1991;9:11–5; discussion 33-34.
80. Shah P, Pellicori P, Hanning I, Zhang J, Clark AL, Bhandari S. The effect of digoxin on renal function in patients with heart failure. BMC Nephrol. 2021;22:349.
81. Redington AN, Carvalho JS, Shinebourne EA. Does digoxin have a place in the treatment of the child with congenital heart disease? Cardiovasc Drugs Ther. 1989;3:21–4.
82. Gonzalez D, Sinha J. Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations. J Clin Pharmacol. 2021;61:S175–87.
83. Alqahtani MA, Alqahtani BA, Dighriri IM. Potential Effects of

Digoxin on Renal Functions in Patients With Congestive Heart Failure. Cureus. 15:e45419.
84. Falconnier AD, Haefeli WE, Schoenenberger RA, Surber C, Martin-Facklam M. Drug Dosage in Patients with Renal Failure Optimized by Immediate Concurrent Feedback. J Gen Intern Med. 2001;16:369–75.
85. Soyka LF. Digoxin: placental transfer, effects on the fetus, and therapeutic use in the newborn. Clin Perinatol. 1975;2:23–35.
86. Malhamé I, Gandhi C, Tarabulsi G, Esposito M, Lombardi K, Chu A, et al. Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia. Obstet Med. 2019;12:66–75.
87. Illamola SM, Bucci-Rechtweg C, Costantine MM, Tsilou E, Sherwin CM, Zajicek A. Inclusion of pregnant and breastfeeding women in research – efforts and initiatives. Br J Clin Pharmacol. 2018;84:215–22.